A randomized trial has found pulsed field ablation to be a more effective first-line treatment for persistent atrial fibrillation than medication. The results of the trial, referred to as AVANT GUARD, suggest that pulsed field ablation may be a viable alternative to traditional drug therapy for initial treatment. The study's findings have been reported as a significant development in the treatment of atrial fibrillation, although one outlet mentioned pulsed-field ablation in the context of paroxysmal atrial fibrillation, introducing some uncertainty about the specific condition being treated.